Amgen announced on Tuesday the submission of a supplemental Biologics License Application to the FDA for Blincyto, or blinatumomab, to include overall survival data from the phase 3 TOWER study, supporting the conversion of Blincyto’s accelerated approval to full approval.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe